Health Risk Assessment of Banned Veterinary Drugs and Quinolone Residues in Shrimp through Liquid Chromatography–Tandem Mass Spectrometry

Abstract

The presence of antibiotic residues in seafood and their effect on public health constitute a matter of concern for consumers worldwide. Antibiotic residues can have adverse effects on both humans and animals, especially residues of banned veterinary drugs. In this study, we applied a validated method to analyze veterinary drug residues in shrimp, including the levels of banned chloramphenicol, malachite green, leucomalachite green, and four nitrofuran metabolites as well as thiamphenicol, florfenicol, and five quinolones, which have no recommended maximum residual levels in shrimp tissues in Taiwan. We collected 53 samples of whiteleg, grass, or giant river shrimp from Taiwanese aquafarms and production areas from July 2016 to December 2017. We found 0.31 ng/g of a chloramphenicol in one grass shrimp, 5.62 ng/g of enrofloxacin in one whiteleg shrimp, 1.52 ng/g of flumequine in one whiteleg shrimp, and 1.01 ng/g of flumequine in one giant river shrimp, indicating that 7.55% of the samples contained veterinary drug residues. We evaluated the health risk by deriving the estimated daily intake (EDI). The quinolone residue EDI was below 1.0% of the acceptable daily intake recommended by the United Nations Food and Agriculture Organization and World Health Organization. The risk was thus discovered to be negligible, indicating no immediate health risk associated with shrimp consumption. The present findings can serve as a reference regarding food safety and in monitoring of the veterinary drug residues present in aquatic organisms. Continual monitoring of residues in shrimp is critical for further assessment of possible effects on human health.

Keywords

• veterinary drug
• residue
• shrimp
• mass spectrometry
• risk assessment